Hemab Therapeutics Holdings, Inc. COAG
—
34.74
(0.98)
(2.74%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 0.0×
Follow COAG
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
35.85 | 12.85 | 18.03 | — |
+1 more quarter Free account |
Net Debt/EBITDA |
17.59 | 6.95 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.94 | 0.95 | — | 1.26 | |
Capex/Depreciation |
(0.31) | (1.53) | — | 0.00 | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(0.75) | (22.93) | — | (16.21) | |
Cash per Share |
15.19 | 172.87 | 0.00 | 0.00 | |
Shareholders Equity per Share |
15.09 | (209.96) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
15.09 | (209.96) | 0.00 | 0.00 | |
Free Cash Flow |
(22.66) | (21.70) | — | (15.33) | |
Working Capital |
451.05 | 156.24 | 181.87 | — | |
Capital Expenditures |
(0.02) | (0.11) | — | 0.00 | |
Net Current Asset Value |
450.49 | (204.44) | (178.87) | 0.00 | |
| Other line items | |||||
Quick Ratio |
35.34 | 12.40 | 17.37 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.75) | (22.82) | — | (16.21) | |
Capex per Share |
0.00 | (0.12) | — | 0.00 | |
Average Assets |
233.89 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | — | 0.00% |
Columns are period end dates